Adiponectin receptor agonist AdipoRon modulates human and mouse platelet function.

Area of Science:

• Cardiovascular Research
• Platelet Biology
• Pharmacology

Background:

• Adiponectin exhibits anti-atherosclerotic and antithrombotic properties.
• AdipoRon is a synthetic agonist for adiponectin receptors.
• Platelet activation is central to arterial thrombosis.

Purpose of the Study:

• To investigate the effects of AdipoRon on human platelet activation.
• To elucidate the molecular mechanisms underlying AdipoRon's action.
• To evaluate AdipoRon's efficacy in an in vivo thrombosis model.

Main Methods:

• In vitro assays using washed human platelets to assess aggregation, secretion, and spreading.
• Western blotting to analyze signaling pathway inhibition (AMPK, Syk, PLCγ2, PI3K, Akt, p38-MAPK, ERK1/2).
• Ferric chloride-induced carotid artery injury model in mice to assess antithrombotic effects.

Main Results:

• AdipoRon dose-dependently inhibited human platelet aggregation, secretion, and spreading.
• AdipoRon suppressed key signaling pathways including AMPK, Syk, PI3K/Akt, and MAPK.
• AdipoRon significantly attenuated arterial thrombosis in a mouse model.
• AdipoR1 deficiency impaired AdipoRon's inhibitory effects on mouse platelets.

Conclusions:

• AdipoRon attenuates platelet function and arterial thrombosis through AdipoR1-mediated signaling.
• The AdipoR1/AMPK/CKII/PI3K/AKT pathway is crucial for AdipoRon's antiplatelet effects.
• AdipoRon presents a promising therapeutic candidate for cardiovascular diseases and antiplatelet therapy.